DMCC Speciality (DMCC)

FairStock Score: 46/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Low leverage with Debt/Equity at 0.29
• Promoter holding at 53.84% provides alignment
• Strong top-line growth of 27.79% shows demand
• ROE of 12.27% and ROCE of 14.08% are decent

Concerns

• Profit fell 21.83% despite 27.79% sales growth, showing margin compression
• Latest quarter net margin is thin at around 4% (₹6 Cr profit on ₹151 Cr sales)
• Valuation is expensive: P/E of 21.32 and P/B of 3.14
• Piotroski F-Score of 4/9 indicates weak financial quality

AI Analysis

Let me look at DMCC Speciality with the same lens I would use for any business: durability, earning power, and price. The balance sheet is acceptable—debt-to-equity of 0.29 and promoters holding 53.84%—so capital is not stretched and owner alignment is good. But the operating story is less reassuring. Sales jumped 27.79%, yet net profit fell 21.83%. In the latest quarter, the company did ₹151 crore of sales but earned only ₹6 crore of net profit, a margin of around 4%. This tells me that revenue growth may be coming at a cost—either through pricing pressure, rising raw material costs, or a weaker product mix. A specialty chemical firm should demonstrate pricing power; here, the numbers don't prove it. ROE is 12.27% and ROCE is 14.08%: respectable but not exceptional. Book value is ₹86.58, while the stock trades at ₹271.75, i.e., 3.14 times book and 21.32 times earnings. That is a premium valuation for a business with declining earnings. The PEG of 0.77 looks superficial because it uses growth that is negative. The Piotroski F-score of 4/9 also suggests weak financial quality, and the FairStock score of 44/100 is mixed. I cannot call this a margin-of-safety purchase. This looks like a cyclical speciality chemical player in a margin squeeze, not a franchise with a wide moat. I would be interested only if profit margins stabilise and recover over several quarters, or if the market offers a much lower price. Until then, I prefer to watch and wait. Price is what you pay; value is what you get. At ₹271.75, I don't get enough.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer